Session » Abstracts: Systemic Sclerosis & Related Disorders – Clinical I (0843–0848)
- 3:00PM-3:15PM
-
Abstract Number: 0843
Efficacy and Safety of BMS-986353, a CD19-Directed Chimeric Antigen Receptor T Cell Therapy Manufactured Using a Next-Generation Process: Updated Data From a Phase 1 Trial in Patients With Systemic Sclerosis
- 3:15PM-3:30PM
-
Abstract Number: 0844
Machine Learning Model Incorporating Baseline and Early Follow-up Clinical Data Predicts 52-Week Cutaneous Outcomes in Systemic Sclerosis
- 3:30PM-3:45PM
-
Abstract Number: 0845
Machine Learning–Based Skin Transcriptome Classifier (v2.0) Links SSc Molecular Subtypes to Disease Severity and Progression
- 3:45PM-4:00PM
-
Abstract Number: 0846
A Longitudinal Transcriptomic Study of Mycophenolate Mofetil in Systemic Sclerosis Skin with Clinical and Molecular Stratification
- 4:00PM-4:15PM
-
Abstract Number: 0847
Interferon Score Effectively Stratifies for Time to Clinically Significant Event Accrual in Systemic Sclerosis Independently of Cutaneous Subset
- 4:15PM-4:30PM
-
Abstract Number: 0848
Spatial Frequency Domain Imaging (SFDI) for Skin Assessment in Systemic Sclerosis: Insights from Histology and Clinical Correlates